News Kelun gets world-first approval for TROP2 ADC Kelun-Biotech has picked up another world-first approval for its TROP2-targeting ADC sac-TMT in non-small cell lung cancer.
News Chaos as layoffs start to hit HHS agencies Job losses start at federal agencies, including HHS, but initial reports suggest some workers who have been let go are quickly being reinstated.
News AstraZeneca joins Pfizer in MFN pricing deal with US AstraZeneca has become the second pharma group to reach an agreement with the Trump administration on Most Favoured Nation (MFN) drug pricing.
News BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.
News UK funds 17 projects on World Mental Health Day With a record number of young people seeking mental health support in the UK, NIHR has awarded £1.5m for digital projects aiming to improve access.
News AZ starts work on Virginia plant in $50bn US investment plan The first stage of AstraZeneca's promised $50 billion investment in US facilities is underway as it breaks ground on a facility in Virginia.
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
